Transitioning from Warfarin to Enoxaparin
Initial Transition Protocol
- The American College of Cardiology recommends discontinuing warfarin 5 days before any planned procedure or when transition to LMWH is required, and beginning enoxaparin when the INR falls below 2.0, with a standard therapeutic dosing of 1 mg/kg subcutaneously twice daily 1, 2, 3
- For patients weighing ≥40 kg/m², consider a reduced dose of 0.8 mg/kg twice daily, as recommended by the National Comprehensive Cancer Network 2
Dosage Adjustments Based on Patient Factors
- For cancer patients, enoxaparin can be dosed at 1 mg/kg every 12 hours (or 1.5 mg/kg once daily after the first month), according to the National Comprehensive Cancer Network 2
Monitoring Protocol
- Anti-Xa activity monitoring is generally not required for most patients on standard doses, but consider monitoring anti-Xa levels in patients with extreme body weight, pregnancy, or recurrent thrombosis despite treatment, as recommended by the National Comprehensive Cancer Network 1, 2, 3
- Monitor for signs of bleeding or thrombosis during the transition period, as advised by the Mayo Clinic Proceedings 1
Duration of Therapy
- For VTE treatment in cancer patients, continue enoxaparin for at least 6 months, as recommended by the National Comprehensive Cancer Network 2, 4
- Resume enoxaparin 24-48 hours after the procedure if hemostasis is adequate, or wait 48-72 hours for high bleeding risk procedures, according to the Mayo Clinic Proceedings 1
Special Considerations
- Enoxaparin is preferred over warfarin for cancer patients with VTE due to lower recurrence rates, as stated by the National Comprehensive Cancer Network 2, 5
- Direct oral anticoagulants (DOACs) are now preferred over warfarin for many patients, but enoxaparin remains important for certain populations, including those with cancer, pregnancy, or requiring bridging therapy, according to the National Comprehensive Cancer Network 2